The prescription opioid, oxycodone, does not alter behavioral measures of impulsivity in healthy volunteers

Pharmacology Biochemistry and Behavior

Volumn 94, Issue 1, 2009, Pages 108-113

  Zacny, James P ^a   de Wit, Harriet ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Humans; Impulsivity; Opioid; Oxycodone; Subjective

Indexed keywords

OXYCODONE;

ADULT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMPULSIVENESS; MALE; MENTAL PERFORMANCE; MOOD CHANGE; NEUROPSYCHOLOGICAL TEST; NORMAL HUMAN; PERSONALITY TEST; PRIORITY JOURNAL; REACTION TIME; TASK PERFORMANCE;

ADULT; AFFECT; ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMPULSIVE BEHAVIOR; MALE; OXYCODONE; PSYCHOLOGICAL TESTS; QUESTIONNAIRES; REWARD; SOCIAL VALUES; SUBSTANCE ABUSE DETECTION; TIME FACTORS; YOUNG ADULT;

EID: 70349260109     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2009.07.010     Document Type: Article

References (60)

1. Acheson A., and de Wit H. Bupropion improves attention but does not affect impulsive behavior in healthy young adults. Exp Clin Psychopharmacol 16 (2008) 113-123
2. Acheson A., Reynolds B., Richards J.B., and de Wit H. Diazepam impairs behavioral disinhibition but not delay discounting or risk taking in healthy adults. Exp Clin Psychopharmacol 14 (2006) 190-198
3. Ainslie G. Specious reward: a behavioral theory of impulsiveness and impulse control. Psychol Bull 82 (1975) 463-496
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders DSM-IV-TR (text revision) (2000), American Psychiatric Association, Washington DC
5. Baddeley A.D. A three-minute reasoning test based on grammatical transformation. Psychon Sci 10 (1968) 341-342
6. Beardsley P.M., Aceto M.D., Cook C.D., Bowman E.R., Newman J.L., and Harris L.S. Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeys. Exp Clin Psychopharmacol 12 (2004) 163-172
7. Bleiberg J., Kane R.L., Reeves D.L., Garmoe W.S., and Halpern E. Factor analysis of computerized and traditional tests used in mild brain injury research. Clin Neuropsychol 14 (2000) 287-294
8. Comer S.D., Sullivan M.A., Whittington R.A., Vosburg S.K., and Kowalczyk W.J. Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers. Neuropsychopharmacology 33 (2008) 1179-1191
9. Denisco R.A., Chandler R.K., and Compton W.M. Addressing the intersecting problems of opioid misuse and chronic pain treatment. Exp Clin Psychopharmacol 16 (2008) 417-428
10. de Wit H. Impulsivity as a determinant and consequence of drug use: a review of underlying processes. Addict Biol 14 (2008) 22-31
11. de Wit, H., Mitchell, S. Drug effects on delay discounting. In: Madden, G.J., Bickel, W.K., Critchfield, T.S., editors. Impulsivity: theory, science, and neuroscience of discounting. Washington DC: American Psychological Association, in press.
12. de Wit H., Crean J., and Richards J.B. Effects of d-amphetamine and ethanol on a measure of behavioral inhibition in humans. Behav Neurosci 114 (2000) 830-837
13. de Wit H., Enggasser J.L., and Richards J.B. Acute administration of d-amphetamine decreases impulsivity in healthy volunteers. Neuropsychopharmacology 27 (2002) 813-825
14. Deneau G., and Seevers M.H. Studies in the monkey (Macacca mulatta) designed to determine the value of this animal for predicting addiction liability to the newer synthetic analgesics. Bull Drug Addiction Narcotics (1957) 1709-1710 Appendix N
15. Epstein D.H., Preston K.L., and Jasinski D.R. Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol. Biol Psychol 73 (2006) 90-99
16. Fraser H.F., van Horn G.D., Martin W.R., Wolbach A.B., and Isbell H. Methods for evaluating addiction liability. (a) "attitude" of opiate addicts toward opiate-like drugs, (b) a short-term "direct" addiction test. J Pharmacol Exp Ther 133 (1961) 371-387
17. Grach M., Massalha W., Pud D., Adler R., and Eisenberg E. Can coadministration of oxycodone and morphine produce analgesic synergy in humans? An experimental cold pain study. Br J Clin Pharmacol 58 (2004) 235-242
18. Haertzen C.A. Development of scales based on patterns of drug effects, using the Addiction Research Center Inventory (ARCI). Psychol Rep 18 (1966) 163-194
19. Hamidovic A., Kang U.J., and de Wit H. Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. J Clin Psychopharmacol 28 (2008) 45-51
20. Heiskanen T., and Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain 73 (1997) 37-45
21. Kalso E. How different is oxycodone from morphine? (Editorial). Pain 132 (2007) 227-228
22. Kieres A.K., Hausknecht K.A., Farrar A.M., Acheson A., de Wit H., and Richards J.B. Effects of morphine and naltrexone on impulsive decision making in rats. Psychopharmacology 173 (2004) 167-174
23. Kirby K.N., Petry N.M., and Bickel W.K. Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls. J Exp Psychol Gen 128 (1999) 78-87
24. Ladd L.A., Kam P.C., Williams D.B., Wright A.W.E., Smith M.T., and Mather L.E. Ventilatory responses of healthy subjects to intravenous combinations of morphine and oxycodone under imposed hypercapnic and hypoxaemic conditions. Br J Clin Pharmacol 59 (2005) 524-535
25. Lalovic B., Kharasch E., Hoffer C., Risler L., Liu-Chen L.-Y., and Shen D.D. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating metabolites. Clin Pharmacol Ther 79 (2006) 461-479
26. Lejuez C.W., Read J.P., Kahler C.W., Richards J.B., Ramsay S.E., Stuart G.L., Strong D.R., and Brown R.A. Evaluation of a behavioral measure of risk taking: the balloon analogue risk task (BART). J Exp Psychol Appl 8 (2002) 75-84
27. Logan G.D., and Cowan W.B. On the ability to control thought and action: a theory of an act of control. Psychol Rev 91 (1984) 295-327
28. Logan G.D., Schachar R.J., and Tannock R. Impulsivity and inhibitory control. Psychol Sci 8 (1997) 60-64
29. Madden G.J., Petry N.M., Badger G.J., and Bickel W.K. Impulsive and self control choices in opioid dependent patients and non-drug-using control participants: drug and monetary rewards. Exp Clin Psychopharmacol 5 (1997) 256-262
30. Mandema J.W., Kaiko R.F., Oshlack B., Reder R.F., and Stanski D.R. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol 42 (1996) 747-756
31. Martin W.R., Sloan J.W., Sapira J.D., and Jasinski D.R. Physiologic, subjective and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12 (1971) 245-258
32. McDonald J., Schleifer L., Richards J.B., and de Wit H. Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology 28 (2003) 1356-1365
33. Mischel W., Shoda Y., and Rodriguez M.L. Delay of gratification in children. Science 244 (1989) 933-938
34. Mitchell S.H. Measures of impulsivity in cigarette smokers and nonsmokers. Psychopharmacology 146 (1999) 455-464
35. Mitchell J.M., Fields H.L., D'Esposito M., and Boettiger C.A. Impulsive responding in alcoholics. Alcohol Clin Exp Res 29 (2005) 2158-2169
36. Myerson J., Green L., and Warusawitharana M. Area under the curve as a measure of discounting. J Exp Anal Behav 76 (2001) 235-243
37. Newman J.P., Widom C.S., and Nathan S. Passive avoidance in syndromes of disinhibition: psychopathology and extraversion. J Pers Soc Psychol 48 (1985) 1316-1327
38. Nielsen C.K., Ross F.B., Lotfipour S., Saini K.S., Edwards S.R., and Smith M.T. Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain. Pain 132 (2007) 289-300
39. Pattij T, Schetters D, Janssen MC, Wiskerke J, Schoffelmeer AN. Acute effects of morphine on distinct forms of impulsive behavior in rats. Psychopharmacology 2009;205:489-502.
40. Patton J.H., Stanford M.S., and Barratt E.S. Factor structure of the Barratt impulsiveness scale. J Clin Psychol 6 (1995) 768-774
41. Pitts R.C., and McKinney A.P. Effects of methylphendiate and morphine on delay-discounting functions obtained within sessions. J Exp Anal Behav 83 (2005) 297-314
42. Poyhia R., Seppala T., Olkkola K.T., and Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 33 (1992) 617-621
43. Preston K.L., Bigelow G.E., Bickel W.K., and Liebson I.A. Drug discrimination in human postaddicts: agonist-antagonist opioids. J Pharmacol Exp Ther 250 (1989) 184-196
44. Rachlin H., and Green L. Commitment, choice, and self-control. J Exp Anal Behav 17 (1972) 15-22
45. Reynolds R., Richards J.B., and de Wit H. Acute-alcohol effects on the Experiential Discounting Task (EDT) and a question-based measure of delayed discounting. Pharmacol Biochem Behav 83 (2006) 194-202
46. Reynolds R., Richards J.B., Dassinger M., and de Wit H. Therapeutic doses of diazepam do not alter impulsive behavior in humans. Pharmacol Biochem Behav 79 (2004) 17-24
47. Richards J.B., Zhang L., Mitchell S., and de Wit H. Delay and probability discounting in a model of impulsive behavior: effect of alcohol. J Exp Anal Behav 71 (1999) 121-143
48. Ross F.B., and Smith M.T. The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain 73 (1997) 151-157
49. Ross F.B., Wallis S.C., and Smith M.T. Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats. Pain 84 (2000) 421-428
50. Stanford M.S., Mathias C.W., Dougherty D.M., Lake S.L., Anderson N.E., and Patton J.H. Fifty years of the Barratt Impulsiveness Scale: an update and review. Pers Indiv Differ 47 (2009) 385-395
51. Substance Abuse and Mental Health Services Administration (SAMHSA), Office of Applied Studies. Results from the 2007 National Survey on Drug Use and Health: national findings (NHDUH Series H-34, DHHS Publication No. SMA 08-4343);2008. Rockville, MD.
52. Tesch A.D., and Sanfey A.G. Models and methods in delay discounting. Ann N Y Acad Sci 1128 (2008) 90-94
53. Walsh S.L., Nuzzo P.A., Lofwall M.R., and Holtman Jr. J.R. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug Alcohol Depend 98 (2008) 191-202
54. Wechsler D. The measurement and appraisal of adult intelligence (1958), Williams and Wilkins, Baltimore MD
55. Zacny J.P., and Gutierrez S. Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. Psychopharmacology 170 (2003) 242-254
56. Zacny J.P., and Gutierrez S. Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers. Drug Alcohol Depend 101 (2009) 107-114
57. Zacny J.P., and Lichtor S.L. Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers. Psychopharmacology 196 (2008) 105-116
58. Zacny J.P., Lichtor J.L., Zaragoza J.G., and de Wit H. Subjective and behavioral responses to intravenous fentanyl in healthy volunteers. Psychopharmacology 107 (1992) 319-326
59. Zacny J.P., Lichtor J.L., Flemming D., Coalson D.W., and Thompson W.K. A dose-response analysis of the subjective, psychomotor, and physiological effects of intravenous morphine in healthy volunteers. J Pharmacol Exp Ther 268 (1994) 1-9
60. Zacny J., Bigelow G., Compton P., Foley K., Iguchi M., and Sannerud C. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend 69 (2003) 215-232